Header image

TRANSLATING BREAKTHROUGHS TO NEXT GENERATION THERAPIES FOR ALS

Tracks
SPEAKER'S ROOM 1: DOROTEA BARNÉS
Wednesday, September 30, 2026
10:15 - 11:00
SPEAKERS' CORNER 1: DOROTEA BARNÉS

Overview

Sponsor: Euskadi


Details

Amyotrophic Lateral Sclerosis (ALS) poses major scientific, clinical, and societal challenges. At the same time, unprecedented advances in molecular biology, drug discovery, biomarkers, precision medicine, and advanced therapeutic approaches are transforming the landscape of neurological research and care. This round table will bring together leading experts from academia, biotechnology, and clinical practice to discuss the latest innovations driving the development of next-generation therapies for ALS. The discussion will explore emerging therapeutic strategies, including novel small molecules, biologics, regenerative and gene-based approaches, as well as the critical role of translational research in accelerating their path to patients. Participants will examine how cutting-edge discoveries are being validated through clinical studies and real-world evidence, addressing key challenges related to efficacy assessment, biomarker development, patient stratification, regulatory pathways, and long-term outcomes. Particular attention will be paid to cross-disciplinary collaboration and innovation. The session will provide a comprehensive perspective on how scientific breakthroughs are advancing from the laboratory to clinical validation and, ultimately, to improved patient outcomes. Key themes: -Advanced therapeutic approaches for ALS -Translational pathways from discovery to clinical application -Biomarkers and patient stratification for precision neurology -Clinical trial innovation and real-world evidence generation -Collaboration between academia, healthcare systems, and biotech companies -Future opportunities and challenges in neurodegenerative disease treatment development This discussion will offer attendees a unique opportunity to gain insights into the evolving neurodegenerative disease ecosystem and the strategies shaping the next generation of therapeutic innovation.


Speaker

Maite Solas
Vice-president
FUNDELA

Moderator

Agenda Item Image
Manuel Cuervas-Mons Cantón
Medical Lead Innovative Medicines
Bristol Myers Squibb

.

Agenda Item Image
Yosu Vara
Chemistry and Manufacturing Director
Quimatriyx

.

Adolfo José Lopez de Munain
Miramoon Pharma & SEED-ALS coordinator/leader
Osakidetza, IIS Biogipuzkoa, Miramoon Pharma

.

Agenda Item Image
Ana Martinez Gil
Profesor de Investigación CSIC y Cofundadora de Molefy Pharma
CIB-CSIC

.

loading